Vasculitis trials
Trials closed to recruitment, in follow-up
COMBIVAS
The principle of using multiple agents to target different disease mechanisms is gaining traction in many autoimmune disease settings. This trial will study the combination of rituximab and belimumab in anti-neutrophil cytoplasmic antibody (ANCA…
